VEST
The VEST Prevention of Early Sudden Death trial explores the hypothesis that wearable cardioverter defibrillators can impact mortality by reducing sudden death in the first 3 months after a heart attack in patients at high risk for life-threatening arrhythmias. This is a vulnerable period for these patients because they don’t yet meet guidelines for receiving implantable cardioverter defibrillators.
These eagerly awaited results, to be presented by Jeffrey E. Olgin, MD, will certainly influence clinical practice, Dr. Kates concluded.